

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin* 2011;61:69–90.
3. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. *Nat Genet* 2012;44:685–689.
4. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. *Nature* 2011;470:214–220.
5. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. *Nature* 2012;487:239–243.
6. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. *Cell* 2013;153:666–677.
7. Weischenfeldt J, Simon R, Feuerbach L, et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. *Cancer Cell* 2013;23:159–170.
8. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science* 2005;310:644–648.
9. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. *Nat Rev Cancer* 2008;8:497–511.
10. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. *J Clin Oncol* 2011;29:3659–3668.
11. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. *Nat Med* 2010;16:793–798.
12. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. *Nat Rev Cancer* 2001;1:34–45.
13. Knudsen BS, Vasioukhin V. Mechanisms of prostate cancer initiation and progression. *Adv Cancer Res* 2010;109:1–50.
14. Abate-Shen C, Shen MM, Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. *Differentiation* 2008;76:717–727.
15. Gurel B, Ali TZ, Montgomery EA, et al. NKX3.1 as a marker of prostatic origin in metastatic tumors. *Am J Surg Pathol* 2010;34:1097–1105.
16. Bhatia-Gaur R, Donjacour AA, Scialolino PJ, et al. Roles for Nkx3.1 in prostate development and cancer. *Genes Dev* 1999;13:966–977.
17. Bova GS, Carter BS, Bussemakers MJ, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. *Cancer Res* 1993;53:3869–3873.
18. Thangapazham R, Saenz F, Katta S, et al. Loss of the NKX3.1 tumor suppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. *BMC Cancer* 2014;14:16.
19. Kaestner KH. The FoxA factors in organogenesis and differentiation. *Curr Opin Genet Dev* 2010;20:527–532.
20. Angello MA, Hickey TE, Knudsen KE. FOXA1: master of steroid receptor function in cancer. *Embo J* 2011;30:3885–3894.
21. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. *N Engl J Med* 2003;349:366–381.
22. Chang KH, Li R, Papari-Zareei M, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. *Proc Natl Acad Sci U S A* 2011;108:13728–13733.
23. Li R, Evalul K, Sharma KK, et al. Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. *Clin Cancer Res* 2012;18:3571–3579.
24. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. *Cancer Res* 2007;67:5033–5041.
25. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. *Cancer Res* 2008;68:4447–4454.
26. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. *Am J Pathol* 2004;164:217–227.
27. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. *Cancer Res* 2006;66:2815–2825.
28. Hoffland J, van Weerden WM, Dits NF, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. *Cancer Res* 2010;70:1256–1264.
29. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. *J Urol* 1993;149:607–609.
30. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* 2009;324:787–790.
31. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. *Nat Med* 2004;10:33–39.
32. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med* 2012;367:1187–1197.
33. Myung JK, Banuelos CA, Fernandez JG, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. *J Clin Invest* 2013;123:2948–2960.
34. Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. *Cancer Res* 2009;69:8141–8149.
35. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. *J Cell Biochem* 2004;91:483–490.
36. Linja MJ, Savinainen KJ, Saramaki OR, et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. *Cancer Res* 2001;61:3550–3555.
37. Giubellino A, Bullova P, Nolting S, et al. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. *Endocrinology* 2013;154:646–655.
38. Yuan X, Cai C, Chen S, et al. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. *Oncogene* 2014;33:2815–2825.
39. Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. *Cancer Res* 2008;68:5469–5477.
40. Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. *Cancer Res* 2014;74:2270–2282.
41. Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. *Cancer Res* 2013;73:483–489.
42. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. *Cancer Cell* 2011;19:575–586.
43. Mulholland DJ, Tran LM, Li Y, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. *Cancer Cell* 2011;19:792–804.
44. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. *Cancer Cell* 2010;18:11–22.
45. Cairns P, Okami K, Halachmi S, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. *Cancer Res* 1997;57:4997–5000.
46. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. *Nat Genet* 2009;41:619–624.
47. Chen M, Pratt CP, Zeeman ME, et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. *Cancer Cell* 2011;20:173–186.
48. McMenamin ME, Soung P, Perera S, et al. Frequent PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. *Cancer Res* 1999;59:4291–4296.
49. Krohn A, Diedler T, Burkhardt L, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. *Am J Pathol* 2012;181:401–412.
50. Sun X, Huang J, Homma T, et al. Genetic alterations in the PI3K pathway in prostate cancer. *Anticancer Res* 2009;29:1739–1743.
51. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. *Cancer Res* 2007;67:8504–8510.
52. Udayakumar T, Shareef MM, Diaz DA, et al. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. *Semin Radiat Oncol* 2010;20:258–266.
53. Sharma A, Yeow WS, Ertel A, et al. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. *J Clin Invest* 2010;120:4478–4492.
54. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. *Nature* 2007;448:595–599.
55. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. *Neoplasia* 2008;10:177–188.
56. Attard G, de Bono JS, Clark J, et al. Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies. *Clin Cancer Res* 2010;16:1340; author reply.
57. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. *Oncogene* 2007;26:4596–4599.
58. Lin DW, Newcomb LF, Brown EC, et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. *Clin Cancer Res* 2013;19:2442–2450.
59. Petterson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2012;21:1497–1509.
60. Borno ST, Fischer A, Kerick M, et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. *Cancer Discov* 2012;2:1024–1035.
61. Demichelis F, Setlur SR, Beroukhi R, et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. *Genes Chromosomes Cancer* 2009;48:366–380.

62. Tomlins SA, Rhodes DR, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. *Cancer Cell* 2008;13:519–528.
63. Bakin RE, Gioeli D, Sikes RA, et al. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. *Cancer Res* 2003;63:1981–1989.
64. Lindberg J, Klevebring D, Liu W, et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. *Eur Urol* 2013;63:347–353.
65. Geng C, He B, Xu L, et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. *Proc Natl Acad Sci U S A* 2013;110:6997–7002.
66. An J, Wang C, Deng Y, et al. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. *Cell Rep* 2014;6:657–669.
67. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. *Cell* 2013;153:666–677.
68. Liu W, Lindberg J, Sui G, et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. *Oncogene* 2012;31:3939–3948.
69. Ateq B, Tomlins SA, Laxman B, et al. Therapeutic targeting of SPINK1-positive prostate cancer. *Sci Transl Med* 2011;3:72ra17.
70. Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discov* 2013;3:636–647.
71. Knudsen BS, Gmyrek CA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. *Urology* 2002;60:1113–1117.
72. Zhang S, Zhou HE, Osunkoya AO, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. *Mol Cancer* 2010;9:9.
73. Verras M, Lee J, Xue H, et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. *Cancer Res* 2007;67:967–975.
74. Jensen AR, David SY, Liao C, et al. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. *Clin Cancer Res* 2011;17:3112–3122.
75. Varkaris A, Katsiampoura AD, Araujo JC, et al. Src signaling pathways in prostate cancer. *Cancer Metastasis Rev* 2014;33(2–3):595–606.
76. Cai H, Smith DA, Memarzadeh S, et al. Differential transformation capacity of Src family kinases during the initiation of prostate cancer. *Proc Natl Acad Sci U S A* 2011;108:6579–6584.
77. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. *Cancer Res* 2008;68:3323–3333.
78. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. *Nature* 2002;419:624–629.
79. Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. *Science* 2012;338:1465–1469.
80. Asangani IA, Ateq B, Cao Q, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. *Mol Cell* 2013;49:80–93.
81. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. *Endocr Relat Cancer* 2012;19:R187–R204.
82. Kiskowski MA, Jackson RS 2nd, Banerjee J, et al. Role for stromal heterogeneity in prostate tumorigenesis. *Cancer Res* 2011;71:3459–3470.
83. Chung LW, Baseman A, Assikis V, et al. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. *J Urol* 2005;173:10–20.
84. Camacho DF, Pienta KJ. Disrupting the networks of cancer. *Clin Cancer Res* 2012;18:2801–2808.
85. Msaouel P, Nandikolla G, Pneumaticos SC, et al. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. *Expert Opin Investig Drugs* 2013;22:1385–1400.
86. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* 2004;303:848–851.
87. Jossan S, Sharp S, Sung SY, et al. Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. *J Oncol* 2010;2010.
88. Goldstein AS, Witte ON. Does the microenvironment influence the cell types of origin for prostate cancer? *Genes Dev* 2013;27:1539–1544.
89. Wang R, Sun X, Wang CY, et al. Spontaneous cancer-stromal cell fusion as a mechanism of prostate cancer androgen-independent progression. *PLoS One* 2012;7:e42653.
90. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med* 2012;366:883–892.
91. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010;363:411–422.
92. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *J Clin Oncol* 2010;28:1099–1105.
93. Sfanos KS, Bruno TC, Meeker AK, et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. *Prostate* 2009;69:1694–1703.
94. Kwek SS, Cha E, Fong L. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. *Nat Rev Cancer* 2012;12:289–297.
95. Palmgren JS, Karavadia SS, Wakefield MR. Unusual and underappreciated: small cell carcinoma of the prostate. *Semin Oncol* 2007;34:22–29.
96. Tan S, Sood A, Rahimi H, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. *Clin Cancer Res* 2014;20:890–903.
97. Chu GC, Zhou HE, Wang R, et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. *Endocr Relat Cancer* 2014;21:311–326.
98. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. *Cancer Discov* 2011;1:487–495.
99. Bernstein BE, Birney E, Dunham I, et al. An integrated encyclopedia of DNA elements in the human genome. *Nature* 2012;489:57–74.
100. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. *Cancer Discov* 2011;1:391–407.
101. Prensner JR, Chen W, Iyer MK, et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. *Cancer Res* 2014;74:1651–1660.
102. Prensner JR, Iyer MK, Sahu A, et al. The long noncoding RNA SCHLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. *Nat Genet* 2013;45:1392–1398.